30 units semaglutide A new study conducted by leading researchers across the United States suggests GLP-1s could have a much greater impact beyond obesity. Link in bio 20 units of semaglutide is

Curcumin, the active component in turmeric, has potent anti-inflammatory and antioxidant properties

Who Should NOT Take Semaglutide Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known hypersensitivity or allergy to Semaglutide Current or planned pregnancy Breastfeeding mothers History of pancreatitis Drug Interactions Insulin and sulfonylureas - may need dose adjustment to prevent low blood sugar Oral contraceptives - absorption may be affected

Regulatory Statement: The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions

These evolving requirements are fostering a digitally secure infrastructure, significantly elevating the demand for blockchain solutions in the healthcare sector GLP-1 Receptor Agonists Obesity Drugs Market Analysis GLP-1 receptor agonists, a class of drugs that mimic the glucagon-such as peptide-1 hormone, are increasingly recognized as powerful therapeutic options for obesity management due to their dual benefits in appetite regulation and blood glucose control, making them essential tools in both endocrinology and weight-loss medicine The accelerating demand for GLP-1 receptor agonists is primarily driven by the global surge in obesity and type 2 diabetes cases, strong clinical outcomes demonstrating significant weight reduction, and growing medical and consumer acceptance of pharmacological obesity treatment North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, characterized by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide, with the U.S

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2025 increased slightly relative to September 2025 (+5.0%) and now account for more than 7% of all prescriptions